financetom
Business
financetom
/
Business
/
US business borrowing for equipment rises over 5% in October, ELFA says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US business borrowing for equipment rises over 5% in October, ELFA says
Nov 24, 2025 12:40 PM

Nov 24 (Reuters) - U.S. companies borrowed 5.7% more to

finance equipment purchases in October than a year earlier,

showing little impact from the recent government shutdown, the

Equipment Leasing and Finance Association said on Monday.

New loans, leases and lines of credit signed up by companies

in October was $10.5 billion on a seasonaly adjusted basis, same

as in the previous month.

At the current pace, 2025 is on track to be the

second-strongest year for equipment demand since ELFA's CapEx

Finance Index (CFI) survey began in 2006, according to the

report.

The Washington-based trade association, which tracks

economic activity in the equipment sector valued at more than $1

trillion, said banks recorded the biggest increase in new

business volumes in October, with an additional $4.8 billion.

"The path for interest rates remains uncertain, but that

doesn't change the fact that our industry is financially

healthy, setting us up for a strong start to 2026," ELFA

President and CEO Leigh Lytle said.

The ELFA CapEx Finance Index of leasing and finance activity

is based on a 25-member survey, including Bank of America ( BAC )

as well as the financing units of Caterpillar ( CAT ),

Dell Technologies ( DELL ), Siemens AG, Canon

and Volvo AB.

The Equipment Leasing & Finance Foundation, ELFA's

non-profit affiliate, sees its November confidence index

relatively unchanged at 59.9 from 60.1 in October. A reading

above 50 indicates a positive business outlook.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Copyright 2023-2025 - www.financetom.com All Rights Reserved